Communiqués Johnson & Johnson Swiss Exchange

Actions

JNJ

US4781601046

Marché Fermé - Swiss Exchange Autres places de cotation 17:36:28 25/05/2023			Varia. 5j.	Varia. 1 janv.
136 ^USD	-0,73%		-0,73%	-.--%

08/06	Les principaux cabinets d'avocats impliqués dans les procès sur les opioïdes aux États-Unis recevront des centaines de millions de dollars d'honoraires	RE
07/06	Les actions de Rapport Therapeutics, soutenues par J&J, augmentent de près de 6 % au début de la séance	RE

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Johnson & Johnson : DePuy Synthes Receives 510(k) FDA Clearance of the VELYS™ Robotic-Assisted Solution for Use in Unicompartmental Knee Arthroplasty Procedures	07/06	PU
Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX	05/06	AQ
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results	04/06	BU
Johnson & Johnson : showcases innovation and leadership in rheumatology at EULAR 2024 Congress	04/06	PU
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	04/06	AQ
Johnson & Johnson Completes Acquisition of Shockwave Medical	03/06	AQ
Johnson & Johnson - First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration	03/06	AQ
Johnson & Johnson Executive Vice President, William N. Hait, M.D., Ph.D., to Retire, Effective September 2024	31/05	AQ
Johnson & Johnson Completes Acquisition of Shockwave Medical	31/05	BU
Johnson & Johnson : to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) Press Release	29/05	PU
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results	29/05	AQ
Johnson & Johnson : to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) Transcript	29/05	PU
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis	28/05	AQ
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis	28/05	BU
Johnson & Johnson: Meet a nurse who leads clinical trials to find innovative cancer therapies	24/05	AQ
Johnson & Johnson : advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA	24/05	PU
Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation	22/05	BU
Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences	22/05	AQ
TREMFYA (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission	21/05	AQ
Novel biologic could offer ulcerative colitis symptomatic remission	21/05	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Joseph Wolk, CFO de J&J: Perte d'exclusivité de son médicament phare

Le 23 janvier 2024 à 18:30